HRA00242-C004 / Jiangsu Hengrui Pharma - LARVOL DELTA

HRA00242-C004, a novel anti-PSMA ADC with high DAR reveals potent in vitro and in vivo anti-tumor efficacy (AACR 2024) - "Meanwhile, as employing the same linker-payload as SHR-A1811, HRA00242-C004 has potential good plasma stability which was consistent with the results of PK study. 2006; 30: 628-36.5.Front Oncol. 2018; 8: 653-63."

Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1